Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 -- Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of...

Related Keywords

Japan ,Massachusetts ,United States ,Paris ,France General ,France ,China ,Nathalie Pham ,Sandrine Guendoul ,Evan Berland ,Hannah Kwagh ,Timothy Gilbert ,Georged Yancopoulos ,Regeneron Velocimmune ,Arnaud Delepine ,Tarik Elgoutni ,Vesna Tosic ,Corentine Driancourt ,Eva Schaefer Jansen ,Felix Lauscher ,Regeneron Genetics Center ,Instagram ,Committee For Medicinal Products Human Use ,Regeneron Pharmaceuticals Inc ,Euronext ,Drug Administration ,Facebook ,Dupilumab Development Program ,Nasdaq ,Exchange Commission ,European Union ,European Medicines Agency ,Linkedin ,Clinical Research Program ,Us Department Of Justice ,Biologics License Application ,Medicinal Products ,Human Use ,Chief Scientific Officer ,Nasal Polyposis ,Prescribing Information ,Regeneron Genetics ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,